ES2524645A1 - Oral formulation for the treatment of cardiovascular diseases (Machine-translation by Google Translate, not legally binding) - Google Patents
Oral formulation for the treatment of cardiovascular diseases (Machine-translation by Google Translate, not legally binding) Download PDFInfo
- Publication number
- ES2524645A1 ES2524645A1 ES201330841A ES201330841A ES2524645A1 ES 2524645 A1 ES2524645 A1 ES 2524645A1 ES 201330841 A ES201330841 A ES 201330841A ES 201330841 A ES201330841 A ES 201330841A ES 2524645 A1 ES2524645 A1 ES 2524645A1
- Authority
- ES
- Spain
- Prior art keywords
- translation
- treatment
- machine
- legally binding
- google translate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title description 2
- 239000000203 mixture Substances 0.000 title description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
P201330841 05-11-2013 P201330841 11-05-2013
Condiciones de la prueba de disolución: Aparato: USP 1 (cesto) Velocidad de agitación: 100 rpm Dissolution test conditions: Device: USP 1 (basket) Stirring speed: 100 rpm
5 Volumen de disolución: 900 ml Medio de disolución: tampón fosfato a pH 6,8 5 Solution volume: 900 ml Dissolution medium: phosphate buffer at pH 6.8
Los resultados (tabla 11 y figura 5) fueron los siguientes: The results (table 11 and figure 5) were the following:
10 Tabla 11: resultados de disolución de % de AAS disuelto en cápsulas de AAR 10 Table 11: dissolution results of% of ASA dissolved in AAR capsules
- Cápsula de AAR AAR capsule
- Tiempo (min) Time (min)
- % de AAS disuelto % of dissolved AAS
- 0 0
- 0 0
- 15 fifteen
- 73,1 73.1
- 20 twenty
- 86,2 86.2
- 30 30
- 95,3 95.3
- 45 Four. Five
- 97,3 97.3
Como se muestra en la tabla 10 y la tabla 11, la cápsula de AAR que contenía comprimidos de AAS de 50 mg x2 recubiertos con película, que comprendían un recubrimiento de comprimido de 8,7 mg/cm2, muestra valores medios superiores al As shown in Table 10 and Table 11, the AAR capsule containing 50 mg x2 film-coated AAS tablets, comprising a tablet coating of 8.7 mg / cm2, shows average values greater than
15 80 % a los 15 minutos en el caso de pH 4,5 y próximos al 75 % a pH 6,8. 15 80% at 15 minutes in the case of pH 4.5 and close to 75% at pH 6.8.
Una formulación que comprende comprimidos de AAS con un recubrimiento de 8,7 mg/cm2 proporciona más protección y aislamiento al comprimido de ácido acetilsalicílico, haciendo más difícil que el ácido salicílico sublime y desencadene la A formulation comprising ASA tablets with a coating of 8.7 mg / cm2 provides more protection and isolation to the acetylsalicylic acid tablet, making it more difficult for sublime salicylic acid to trigger
20 degradación de los demás componentes, en particular, de la atorvastatina o la rosuvastatina, dentro de la cápsula final. Degradation of the other components, in particular, of atorvastatin or rosuvastatin, within the final capsule.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330841A ES2524645B1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330841A ES2524645B1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2524645A1 true ES2524645A1 (en) | 2014-12-10 |
| ES2524645B1 ES2524645B1 (en) | 2015-12-02 |
Family
ID=52004086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201330841A Active ES2524645B1 (en) | 2013-06-06 | 2013-06-06 | Oral formulation for the treatment of cardiovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2524645B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2307463T1 (en) * | 2001-08-28 | 2008-12-01 | Longwood Pharmaceutical Research, Inc. | COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL REDUCING AGENT, A RENIN-ANGIOTENSIN INHIBITOR, AND AN ASPIRINE. |
| WO2012002919A1 (en) * | 2010-06-30 | 2012-01-05 | Mahmut Bilgic | Pharmaceutical formulations comprising atorvastatin and aspirin |
| WO2012081905A2 (en) * | 2010-12-17 | 2012-06-21 | Hanmi Holdings Co. , Ltd. | Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin |
| WO2012124973A2 (en) * | 2011-03-15 | 2012-09-20 | Boryung Pharmaceutical Co., Ltd | Combined formulation with improved stability |
-
2013
- 2013-06-06 ES ES201330841A patent/ES2524645B1/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2307463T1 (en) * | 2001-08-28 | 2008-12-01 | Longwood Pharmaceutical Research, Inc. | COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL REDUCING AGENT, A RENIN-ANGIOTENSIN INHIBITOR, AND AN ASPIRINE. |
| WO2012002919A1 (en) * | 2010-06-30 | 2012-01-05 | Mahmut Bilgic | Pharmaceutical formulations comprising atorvastatin and aspirin |
| WO2012081905A2 (en) * | 2010-12-17 | 2012-06-21 | Hanmi Holdings Co. , Ltd. | Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin |
| WO2012124973A2 (en) * | 2011-03-15 | 2012-09-20 | Boryung Pharmaceutical Co., Ltd | Combined formulation with improved stability |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2524645B1 (en) | 2015-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0606883A2 (en) | pharmaceutical composition for oral administration, method for preparing a tablet, and single solid dosage form | |
| FI2508188T3 (en) | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate | |
| GT201000275A (en) | CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES | |
| DOP2012000264A (en) | PHARMACEUTICAL FORMULATION IN THE FORM OF TWO-COATED TABLETS THAT INCLUDE INHIBITOR OF HMG-COA REDUCTASA AND IRBESARTAN | |
| PH12017500269B1 (en) | Composite formulation for oral administration comprising omega-3 fatty acid esters and statins | |
| CO7350622A2 (en) | Formulation of a compound pharmaceutical capsule comprising irbesartan and hmg-coa reductase inhibitor | |
| CL2013003176A1 (en) | Sustained-release oral pharmaceutical formulation comprising two tablets containing 1000 mg of paracetamol, which is present in a sustained-release layer and another of immediate release, in a proportion of paracetamol per layer of 80-90%: 10-20% , where the unit dose comprises 2000 mg paracetamol. | |
| DOP2015000296A (en) | ORAL FORMULATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | |
| ES2524645A1 (en) | Oral formulation for the treatment of cardiovascular diseases (Machine-translation by Google Translate, not legally binding) | |
| AR095538A1 (en) | PHARMACEUTICAL COMPOSITIONS OF LIPOEQUILIBRATED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL ADMINISTRATION | |
| BR112015005392A2 (en) | tablet formulation of a phosphatidylinositol 3 kinase inhibitor | |
| RU2014146303A (en) | METHOD FOR TREATING ACNES | |
| TH126521A (en) | A pharmaceutical formulation in a two-layer tablet formulation that includes: HMG-COA Reductase Inhibitor and Urbesar Tan | |
| RU2014105690A (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION CONTAINING STATIN | |
| PL400338A1 (en) | Solid oral dosage form comprising sunitinib L-malate | |
| TH133918A (en) | Oral complex consisting of omega-3 fatty acid esters And an HMG-COA reductase inhibitor | |
| DOP2008000034A (en) | PHARMACEUTICAL FORMULATION THAT INCLUDES SIMVASTATIN AND EZETIMIBE | |
| AR097023A1 (en) | COMPOSITION FOR THE MANAGEMENT OF NAUSE AND VOMITS, METHOD FOR RELIEFING THEM, PHARMACEUTICAL DOSAGE SYSTEM | |
| TN2010000445A1 (en) | Oral and injectable formulations of tetracycline compounds | |
| EA201400740A1 (en) | PHARMACEUTICAL COMPOSITIONS OF SEVELAMERA | |
| IN2013MU03765A (en) | ||
| UA99317C2 (en) | Pharmaceutical composition in tablet form for the treatment of viral diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2524645 Country of ref document: ES Kind code of ref document: B1 Effective date: 20151202 |